Persephone Biosciences

Persephone Biosciences is a private, commercial-stage biotech company translating microbiome research into direct-to-consumer wellness products. The company's core offering is a scientifically formulated synbiotic for infants, born from its 'My Baby Biome' study, which identified a widespread deficit of beneficial gut bacteria. While currently generating early revenue from product sales, Persephone's long-term strategy appears to be building a data-rich platform to inform future therapeutic and diagnostic applications in the microbiome space. The company is led by its CEO and co-founder, Dr. Stephanie Culler, a microbiome scientist and mother.

Proprietary microbiome research platform integrating large-scale human studies (e.g., 'My Baby Biome'), deep DNA sequencing, and AI/ML to identify keystone bacterial deficits and rationally design targeted synbiotic (probiotic + prebiotic) formulations.

Persephone competes with numerous probiotic supplement brands (e.g., Culturelle, Garden of Life) and infant formula companies adding probiotics. Its key differentiator is its specific clinical study in infants and its platform approach. In the broader microbiome therapeutics space, it would compete with well-funded biotechs like Seres Therapeutics, Vedanta Biosciences, and many others developing defined microbial consortia for specific diseases.